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IN-1130, a novel transforming growth factor-b type I
receptor kinase (ALK5) inhibitor, suppresses renal
fibrosis in obstructive nephropathy
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The transforming growth factor-b (TGF-b) plays a central role
in the progression of renal fibrosis. TGF-b transduces its
signal through the activin receptor-like kinase (ALK)5.
IN-1130, a novel small molecule ALK5 inhibitor, inhibited
the purified kinase domain of ALK5-mediated Smad3
phosphorylation with an IC50 value of 5.3 nM. IN-1130 proved
to be highly selective in a panel of 27 serine/threonine and
tyrosine kinases including p38a mitogen-activated protein
kinase. We evaluated the efficacy of IN-1130 to block renal
fibrogenesis induced by unilateral ureteral obstruction (UUO)
in rats. Either vehicle (saline) or IN-1130 (10 and 20 mg/kg/
day) was intraperitoneally administered to UUO rats for 7 and
14 days. Phosphorylated Smad2 (pSmad2) and markers of
fibrosis were analyzed in kidney tissues. In UUO control
kidneys, interstitial fibrosis including tubular atrophy, loss
and dilation, inflammatory cell infiltration, and fibroblast cell
proliferation was prominent. These morphological changes
were notably reduced by IN-1130 treatment. IN-1130
decreased levels of TGF-b1 messenger RNA (mRNA), type I
collagen mRNA, and pSmad2, compared to UUO control rats.
As determined by measuring the hydroxyproline content,
total kidney collagen amount was increased in UUO control
kidneys, but significantly reduced by IN-1130 treatment,
which was comparable to results of histochemical staining
for collagen. IN-1130 also suppressed the expression of
a-smooth muscle actin (a-SMA) and fibronectin in UUO
kidneys. Our results show that IN-1130 suppressed the
fibrogenic process of UUO, further underscoring the
potential clinical benefits of IN-1130 in the treatment of
renal fibrosis.
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Transforming growth factor (TGF)-b family has a pivotal
role in the regulation of a variety of physiological processes.
Three TGF-b isoforms (TGF-b1, TGF-b2, and TGF-b3) are
expressed in mammals, and each is encoded by a unique gene
and expressed in a tissue-specific manner. TGF-b signals
through a transmembrane receptor serine/threonine complex
that comprises the type I and type II receptor kinases. Once
activated, TGF-b binds to the constitutively active type II
receptor, and the type I receptor kinase activin receptor-like
kinase (ALK)5 is subsequently recruited into the complex
and is activated by TGF-b type II receptor-mediated
phosphorylation. Phosphorylation of serine/threonine resi-
dues in the ALK5 subsequently phosphorylates the major
downstream signaling molecules Smad2 and 3 proteins.
Phosphorylated Smad2 (pSmad2) and 3 form a complex with
Smad4. This complex translocates into nucleus and regulates
the transcription of specific genes involved in cell growth,
differentiation, development, and immune response.1–5
Deregulation of TGF-b has been implicated in the
pathogenesis of various diseases including fibrosis, athero-
sclerosis, and cancer.3,6–9 Numerous studies have consistently
indicated the role of TGF-b as a potent fibrogenic cytokine
evoking pathological fibrosis in various organs.10–14
Attempts to block the effects of TGF-b have contributed to
the development of molecules that inhibit TGF-b binding to
its receptor including decorin,15–16 soluble chimeric TGF-b
receptor,17–19 and neutralizing antibodies.20–22 The extensive
knowledge regarding TGF-b-mediated ALK5-dependent sig-
naling pathway as an initiating point at the receptor level has
highlighted the therapeutic potential of TGF-b signaling
antagonist. Recent studies have shown that several small
molecule adenosine triphosphate (ATP)-competitive ALK5
inhibitors inhibit or retard progressive fibrosis in kidney,
lung, and liver.23–25
We have synthesized and developed a series of ALK5
inhibitors that possess an imidazole-based molecular scaf-
fold, acting as a competitive inhibitor of the ATP binding site
of ALK5. We previously showed that IN-1130, a representa-
tive molecule of our compounds, inhibited transcription of
reporter genes induced by TGF-b, but did not show
significant activity against p38a mitogen-activated protein
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kinase.26 In addition, IN-1130 effectively prevented hepatic
fibrosis in the bile duct ligated rat model (submitted).
Progressive renal disease is associated with interstitial
fibrosis that is characterized by monocyte infiltration,
fibroblast proliferation/differentiation, and extracellular ma-
trix (ECM) protein accumulation. Interstitial fibrosis is a
common sequel to renal injury and is the final common
pathway in several renal disorders leading to end-stage renal
failure. Various inflammatory mediators such as cytokines,
nitric oxide, and growth factors influence the progression of
renal fibrosis.3,4,27,28 Among them, TGF-b plays a significant
role in the progression of renal fibrosis by inducing the
production of ECM proteins and decreasing enzymes that
degrade excessive ECM.29–31 These points have provided the
therapeutic potential of antagonizing the TGF-b pathway in
renal fibrotic disorders.
In this study, we evaluated the efficacy of IN-1130 for the
treatment of renal fibrosis in a rat unilateral ureteral
obstruction (UUO) model and demonstrated for the first
time that IN-1130 is effective in the prevention and treatment
of renal fibrosis in a rat UUO model.
RESULTS
Selective inhibition of ALK5 by IN-1130
IN-1130 inhibited ALK5 phosphorylation of Smad3 with an
IC50 value of 5.3 nM (Figure 1). The selectivity of IN-1130 for
ALK5 versus other kinases was evaluated using a panel of
various kinases (Table 1). IN-1130 inhibited ALK5 phos-
phorylation of casein with an IC50 values of 36 nM and
inhibited p38a mitogen-activated protein kinase with an IC50
value of 4.3 mM, demonstrating that IN-1130 is approximately
100-fold more selective for ALK5 than p38a. IN-1130
exhibited IC50 values greater than 5 mM for other kinases.
Inhibition of tubulointerstitial nephritis of UUO rats treated
with IN-1130
Histological examination showed that, in UUO control
kidneys, architecture was drastically altered with acute and
chronic tubular damages including tubular atrophy, loss and
dilation, infiltration of inflammatory cells, and development
of interstitial fibrosis (Figure 2). Most prominent damage
was observed in collecting ducts and loops of Henle in
the medulla area, which is characterized by expansion of
interstitial space with the accumulation of fibroblasts and
inflammatory cells at day 7. Tubulointerstitial damage was
more prominent in both cortex and medulla at day 14. These
changes were notably reduced or absent in UUO animals
treated with IN-1130 (Figure 2).
Decreased expression of TGF-b1 in UUO kidneys by IN-1130
treatment
A drastic increase in TGF-b is a key feature of UUO kidney.
Level of TGF-b1 messenger RNA (mRNA) in UUO control
kidneys was increased 4.4- and 4.1-fold at days 7 and 14 after
ureteral ligation, respectively, compared to sham-operated
animals (Figure 3; Po0.01). IN-1130 dose-dependently
decreased levels of TGF-b1 mRNA.
Suppression of phosphorylation of Smad2 in UUO kidneys
by IN-1130
We determined that increase in TGF-b in UUO kidneys is
accompanied by the increase in pSmad2. Western blotting
analysis showed that level of pSmad2 in UUO control kidneys
at day 14 was increased 40-fold compared to sham-operated
kidneys. IN-1130 significantly decreased levels of pSmad2 in
IC50 =  5.3 nM
[IN-1130] (log M )
AL
K5
 p
ho
sp
ho
ry
la
tio
n
o
f S
m
ad
3 
(c.
p.m
.)
0
2000
4000
6000
8000
10,000
12,000
–9 –8 –7 –6
Figure 1 | Dose–response curve of IN-1130 for its inhibitory
effects on the constitutively active TGF-b1 type I receptor
ALK5 (T204D)-mediated Smad3 phosphorylation. Various
concentrations of IN-1130 were mixed with reaction buffer including
purified ALK5 protein (200 ng) and g-32P-ATP. The mixtures were
incubated onto the Smad3-coated Flash-Plates for 3 h. After
incubation, the radioactivities of incorporated g-32P-ATP into the
phosphorylated sites of Smad3 by ALK5 were measured. The in vitro
IC50 value of IN-1130 was calculated from a dose–response curves
generated from two experiments run in duplicate (n¼ 4) using
SigmaPlot software.
Table 1 | IC50 values for IN-1130 against various protein
kinasesa
Protein kinase IC50 (lM) Protein kinase IC50 (lM)
ALK5 0.036b JNK3 30
ABL1 26 MAPKAPK5 4100
ACV-R1 8.5 MST4 4100
ARK5 4100 NEK2 4100
Aurora-A 4100 NLK 29
B-Raf 12 p38a 4.3
CK2a1 4100 PAK1 4100
COT 4100 PDGFR-a 7.8
CSK 32 PIM1 4100
DAPK1 4100 PRK1 4100
FGF-R1 13 S6K 4100
FLT3 4100 SGK1 4100
IGF1-R 4100 SRC 4100
IRAK4 4100 ZAP70 4100
aAll protein kinases were expressed as human recombinant glutathione-S
transferase-fusion proteins or His-tagged proteins in Sf9 insect cells by using a
baculovirus expression system. Kinases were purified by affinity chromatography
using either GSH-agarose or Ni-NTA-agarose. ProQinase GmBH (Freiburg, Germany)
performed radioisotopic protein kinase assays for measuring kinase activities for all
enzymes except for p38a. In vitro kinase inhibition assay of IN-1130 against p38a
was performed in MDS Pharma services. IC50 values were measured by testing 12
concentrations of IN-1130 in each kinase assay. The IC50 values for IN-1130 against
ALK5 were determined from an experiment run in triplicate.
bCasein was used as a substrate. The IC50 values for IN-1130 were determined from
an experiment run in triplicate.
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a dose-dependent manner (Figure 4). Levels of pSmad2 in
sham-operated kindeys and UUO kidneys treated with IN-
1130 were too low to quantitatively measure at day 7 (data
not shown). Next, we performed pSmad2 immunohisto-
chemistry on kidney sections. pSmad2 immunoreactivity was
weak or absent in sham-operated kidneys. Strong pSmad2
immunoreactivity was present in the nuclei of tubular and
interstitial cells in UUO kidneys, whereas weak staining was
observed in UUO kidneys treated with IN-1130 (Figure 5).
Suppression of the expression of a-SMA and myofibroblasts
in UUO kidneys by IN-1130
The appearance of a-smooth muscle actin (a-SMA)-positive
myofibroblasts is considered a key event in the progression of
chronic renal diseases. Western blotting analysis for a-SMA
demonstrated that the level of a-SMA in UUO kidneys
increased approximately 35- and 90-fold at days 7 and 14,
respectively, compared to sham-operated animals (Figure 6;
Po0.01). IN-1130 decreased a-SMA expression in a dose-
dependent manner.
Immunohistochemical staining for a-SMA was performed
to localize the expression of a-SMA on kidney sections
(Figure 7). In UUO control kidneys at day 7, elongated
myofibroblasts stained positively for a-SMA were observed in
interstitial areas, and some a-SMA-positive tubular epithelial
cells were present. The abundance and location of a-SMA
expression in UUO kidneys treated with IN-1130 at a dose of
20 mg/kg/day was similar to that of sham-operated animals.
In kidneys with UUO for 14 days, strong a-SMA immuno-
reactivity was extensively present in tubular and interstitial
cells, but reduced by IN-1130 treatment.
Effect of IN-1130 on the expression of type I collagen mRNA
and on interstitial collagen deposition
Levels of type I collagen mRNA in UUO control kidneys at
days 7 and 14 were increased 3.5- and 9.7-fold, respectively,
compared to sham-operated animals (Figure 8; Po0.01).
IN-1130 treatment dose dependently decreased levels of
type I collagen mRNA both at days 7 and 14.
Total kidney collagen content was determined by measur-
ing the amount of hydroxyproline, a quantitative biochemical
assay. As shown in Figure 9, hydroxyproline contents in the
UUO control kidneys increased to 151 and 245% at days 7
and 14, respectively, compared to that (12.870.7 mg/mg
protein) of normal rats at the starting point (day 0). IN-1130
significantly reduced hydroxyproline contents in UUO
kidneys. We further examined the expression of collagen on
Masson’s trichrome stained kidney sections. The collagen
accumulation were prominent in the interstitial space of
UUO control kidneys, compared to sham-operated animals
(Figure 10). IN-1130 markedly reduced the collagen accu-
mulation in UUO control kidneys (Figure 10).
Effect of IN-1130 on total kidney fibronectin
We also investigated the effect of IN-1130 on the expression
of fibronectin, a major interstitial matrix component, in
UUO kidneys (Figure 11). Compared to sham-operated
animals, UUO kidneys exhibited 17- and 53-fold increases in
the expression of fibronectin at days 7 and 14, respectively.
IN-1130 suppressed the levels of fibronectin in UUO kidneys
in a dose-dependent manner.
DISCUSSION
We previously identified IN-1130 as a potent small molecule
inhibitor of TGF-b signaling pathway in cell-based assays.
The present study clearly shows that IN-1130 effectively
inhibits the in vitro ALK5 activity without affecting other
serine/threonine and tyrosine kinases examined. Recently,
several ALK5 inhibitors have been developed as a potential
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Figure 2 | Representative photomicrographs of hematoxylin–
eosin-stained kidney sections from sham-operated rats, UUO
control rats, and UUO rats treated with IN-1130. (a) In sham
kidney at day 7, no changes were observed. (b) Histopathological
changes manifested by tubular atrophy, loss and dilation, infiltration
of inflammatory cells, and proliferation of fibroblastic cells (arrow
heads) were prominent in UUO control kidneys at day 7 after UUO.
(c) At day 7 after UUO, UUO rats treated once daily with IN-1130
(10 mg/kg) reduced the extent of interstitial nephritis and fibrosis
(arrowheads). (d) At day 7 after UUO, histopathological changes
shown in UUO control kidneys were significantly reduced or absent
by IN-1130 treatment (20 mg/kg). (e) Severe morphological changes
characterized by tubular atrophy and loss, and interstititial expansion
with cellular infiltrates and fibrous components (arrowheads) were
observed in kidneys with UUO for 14 days. Note the remaining
atrophic tubular cells (asterisks) which are surrounded by expanded
interstitium. (f) At day 14 after UUO, UUO rats treated once daily
with IN-1130 (20 mg/kg) reduced the extent of tubular atrophy and
loss, and interstitial nephritis and fibrosis (arrowheads) compared
to UUO control kidneys. Bar¼ 50mm.
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therapy in fibrosis diseases. Among them, SB-525334 is a
small molecule ALK5 inhibitor and has a similar molecular
scaffold with IN-1130.23 We compared the potency of
IN-1130 with SB-525334 and found out that IN-1130 is
more potent than SB-525334 in both enzyme inhibition and
in vitro cell-based assays (data not shown).
The obstructed kidneys at 7 days after ureteral ligation in
the present study showed typical features of obstructive
nephropathy such as the presence of myofibroblasts and
inflammatory cells in the interstitium, tubular degeneration
and atrophy, and interstitial fibrosis. Tubulointerstitial
damages progressed in UUO kidneys at day 14. These
morphological changes are accompanied by increases in the
a
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Figure 3 | Suppression of TGF-b1 mRNA expression in rat UUO kidneys by IN-1130. (a) Representative reverse transcriptase-PCR
photographs (upper panel) showing levels of TGF-b1 mRNA of kidneys from sham-operated rats, UUO control rats, and UUO rats treated
with IN-1130 for 7 and 14 days. Numbers 1 and 2 indicate two individual animals from each group. HPRT served as an internal control.
(b) SYBR Green real-time PCR analysis was used to quantify levels of TGF-b1 mRNA in the kidneys of sham-operated rats, UUO control rats,
and UUO rats treated with IN-1130 for 7 and 14 days. Treatment of IN-1130 (10 and 20 mg/kg/day) significantly decreased the amount of
TGF-b1 mRNA in UUO control kidneys. Values are s.e.m. of 7 (day 7) or 4 (day 14) animals per group. *Po0.05 versus sham control group.
**Po0.01 versus sham control group. #Po0.05 versus UUO control group. ##Po0.01 versus UUO control group.
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Figure 4 | Suppression of phosphorylation of Smad2 in rat UUO
kidneys by IN-1130. (a) Representative Western blotting
photograph (upper panel) showing levels of pSmad2 protein in the
kidneys of sham-operated rats, UUO control rats, and UUO rats once
daily treated with either vehicle or IN-1130 for 14 days. The same blot
was stripped and reprobed with b-actin to confirm equal loading
(lower panel). Numbers 1 and 2 indicate two individual animals from
each group. (b) Quantitative analysis of the relative abundance of
pSmad2 protein after normalization with b-actin. Values (fold
induction relative to sham-operated control) are s.e.m. of four
animals per group. *Po0.05 versus sham control group. **Po0.01
versus sham control group. #Po0.01 versus UUO control group.
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Figure 5 | Representative photomicrographs of pSmad2
immunohistochemistry on kidney sections from sham-operated
rats, UUO control rats, and UUO rats treated with IN-1130.
(a and d) In sham-operated animals, no significant nuclear pSmad2
staining was observed at (a) day 7 and (d) day 14. (b and e) Nuclear
localization of pSmad2 in tubular and interstitial cells was increased in
UUO control kidneys at (b) day 7 and (e) day 14 (brown, arrowheads)
compared to sham-operated kidneys. (c and f) IN-1130 (20 mg/kg)
treatment reduced nuclear staining intensity (brown, arrowheads) in
interstitial and tubular areas of kidneys at (c) day 7 and (f) day 14,
which are associated with the decrease in the extent of interstitial
nephritis and fibrosis compared to UUO control kidneys. Bar¼ 80mm.
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amounts of a-SMA, hydroxyproline, collagen, and fibro-
nectin that are specific biochemical markers for fibrosis.
Our study shows that IN-1130 almost completely suppressed
the expression of a-SMA, collagen, and fibronectin in UUO
kidneys at an early stage (day 7), which is accompanied
by the attenuation of tubulointerstitial fibrosis. Although
IN-1130 did not confer complete protection from renal
fibrosis in UUO kidneys at a later stage (day 14), IN-1130
significantly inhibited fibrogensis in UUO kidneys.
TGF-b is believed to be the prime fibrogenic molecule in
UUO model. A drastic increase in TGF-b1 was observed in
UUO kidneys. Interestingly, IN-1130 treatment decreased the
amount of TGF-b1 mRNA in UUO kidneys being accom-
panied by the attenuation of all fibrogenic features examined.
Decreased TGF-b1 mRNA expression by IN-1130 may be the
indirect consequence of reduced fibrogenic cellular compo-
nents including fibroblasts and myofibroblasts that produce
TGF-b. Also, this reduction of TGF-b1 mRNA by IN-1130
may contribute to less numbers of inflammatory cells such
as macrophages and fibroblasts in the interstitium as TGF-b
is a potent chemoattractant for those cell types.32 Indeed, we
found that IN-1130 decreased the number of infiltrating
macrophages in UUO kidneys which were identified by
immuohistochemistry using a monoclonal ED1 antibody
(data not shown).
In the present study, we did not identify the cellular source
of TGF-b in UUO kidneys, but several reports have indi-
cated that the major cell component that produces TGF-b in
UUO model is interstitial cells. However, a contribution of
tubular cells to the increased TGF-b levels cannot be excluded
as tubular cells are known to upregulate TGF-b.33,34 In the
present study, levels of TGF-b1 mRNA in UUO control
kidneys were similar between at days 7 and 14 after unilateral
ligation, which is consistent with the previous reports
in which, unlike other fibrogenic markers, level of TGF-b
was not prominently elevated from early to late stages.35,36
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Figure 6 | Suppression of a-SMA expression in rat UUO kidneys by IN-1130. (a) Representative Western blotting photographs (upper
panel) showing levels of a-SMA protein in the kidneys of sham-operated rats, UUO control rats, and UUO rats once daily treated with
either vehicle or IN-1130 for 7 and 14 days. The same blot was stripped and reprobed with b-actin to confirm equal loading (lower panel).
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Figure 7 | Representative photomicrographs of a-SMA
immunohistochemistry on kidney sections from sham-operated
rats, UUO control rats, and UUO rats treated with IN-1130. (a, d,
and g) In sham-operated animals , a-SMA expression (brown color) is
limited to blood vessels (arrows). (b and e) Strong immunoreactivity
was observed in interstitial and tubular areas of UUO control kidney
at day 7 after UUO. (h) The extent of a-SMA intensity and the number
of cells expressing a-SMA in UUO control kidney at day 14 was
increased compared to those of UUO control kidney at day 7 (b and
e). (c and f) Once-daily treatment with IN-1130 (20 mg/kg) for 7 and
(i) 14 days reduced staining intensity in interstitial and tubular areas
of kidneys, which is associated with the decrease in the extent of
interstitial nephritis and fibrosis. Bar¼ 30mm.
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This discrepancy may be explained by the observation that,
in the late stage (day 14), more than 60–70% of renal tubular
parenchyma which may produce TGF-b was replaced by
fibrotic components.
IN-1130 suppressed phosphorylation of Smad2, a marker
of TGF-b/ALK5 signaling activation. This reduction of
pSmad2 is well correlated with the reductions seen for
other fibrogenic markers, indicating that pSmad2 is a major
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Figure 8 | Suppression of type 1 collagen mRNA expression in UUO control kidneys by IN-1130. (a) Representative reverse
transcriptase-PCR photograph (upper panel) showing levels of collagen type I mRNA of kidneys from sham-operated rats, UUO control rats, and
UUO rats treated with IN-1130 for 7 and 14 days. Numbers 1 and 2 indicate two individual animals from each group. HPRT served as an internal
control. (b) SYBR Green real-time PCR analysis was used to quantify levels of the collagen type 1 mRNA in the kidneys of sham-operated rats,
UUO control rats, and UUO rats treated with IN-1130 for 7 and 14 days. Treatment of IN-1130 (10 and 20 mg/kg/day) significantly decreased the
amount of type I collagen mRNA in UUO control kidneys. Values are s.e.m. of 7 (day 7) or 4 (day 14) animals per group. *Po0.01 versus sham
control group. #Po0.01 versus UUO control group.
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Figure 9 | Effect of IN-1130 on the hydroxyproline content in UUO
control kidneys. IN-1130 treatment significantly decreased levels of
hydroxyproline in UUO control kidneys at (a) day 7 and (b) day 14.
Values are s.e.m. of 7 (day 7) or 4 (day 14) animals per group. *Po0.05
versus sham control group. **Po0.01 versus sham control group.
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Figure 10 | Representative photomicrographs of Masson’s
trichrome staining on kidney sections from sham-operated rats,
UUO control rats, and UUO rats treated with IN-1130. (a, d, and g) In
sham-operated animals, collagen expression is limited to blood vessels
(blue, arrows). (blue in b and e) Collagen expression is prominent in
interstitial and tubular areas of UUO control kidneys at day 7 after UUO
(b and e). (blue in h) Collagen expression is present in a widespread
pattern at day 14 after UUO. Once-daily treatment with IN-1130
(20 mg/kg) for 7 (c and f) and 14 days (i) reduced staining intensity in
interstitial and tubular areas of kidneys, which is associated with the
decrease in the extent of interstitial nephritis and fibrosis. Collagen is
present only around blood vessels (arrows in c) in UUO kidneys once
daily treated with IN-1130 (20 mg/kg) for 7 days. Bar¼ 30mm.
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downstream signaling molecule in the fibrogenesis of UUO
kidneys. Taken together, our study demonstrates that the
inhibition of ALK5 signaling pathway by IN-1130 could
interfere with the autocrine/paracrine effect of TGF-b in
fibrogenic and inflammatory cells, leading to the blocking of
the vicious fibrosis cycle in UUO model. It should be
mentioned here that this reduction of the number of
fibrogenic cells is not related to the direct effect of IN-1130
on the cell cycle-related events because IN-1130 did not show
an antiproliferative effect on several cell lines in vitro at the
concentration of up to 100 mM (data not shown).
Myofibroblasts are not present in normal kidney. The
appearance of myofibroblast cells expressing a-SMA protein
is one of the early changes leading to fibrosis in the UUO
kidney. a-SMA is considered specific for epithelial myofibro-
blast transdifferentiation. Elongated myofibroblasts expres-
sing a-SMA were found in moderate numbers in fibrotic
interstitium of UUO kidneys, and some tubular epithelial
cells were stained with a-SMA. These findings indicate that
there is a continuous transition between a-SMA-positive
epithelial cells and positively staining cells with myofibroblast
morphology. This event is probably induced by TGF-b that is
increased during the pathogenesis of interstitial nephritis and
fibrosis.
Myofibroblasts have been known to produce interstitial
ECM components such as type I collagen and fibronectin.37
As shown in Figures 7 and 10, in UUO control kidneys, type I
collagen was colocalized on the a-SMA-positive cells in the
interstitium. IN-1130 treatment significantly reduced the
expression of a-SMA-positive cells, type I collagen, and
fibronectin. This finding suggests that blocking of TGF-b
signaling pathway is sufficient to prevent the generation of
ECM components. A similar result was previously obtained
when IN-1130 was used for the treatment of hepatic fibrosis
induced by bile duct ligation in rats in which IN-1130
successfully decreased levels of a-SMA protein and type I
collagen (submitted).
Our study clearly demonstrates that the inhibition of
fibrogenesis in UUO kidneys by interfering TGF-b signaling
is sufficient to prevent the fibrogenesis, which is consistent
with the previous reports in which another TGF-b signaling
antagonists including anti-TGF-b antibody could prevent the
fibrogenic process in UUO kidneys.15–22 Taken together, the
TGF-b signaling pathway plays a major role in fibrogenesis in
UUO kidneys even though the renal fibrosis is considered a
multi-component disease.
However, it should be mentioned here that IN-1130
efficiently ameliorated renal fibrosis, but did not completely
prevent the fibrogenic process in UUO kidneys at the late
stage (day 14). These results suggest that renal fibrosis in
obstructed kidneys at late stages involve TGF-b-dependent as
well as TGF-b-independent pathways. Therefore, IN-1130
could be more effective for the treatment of renal fibrosis
when used in combination with other anti-fibrotic agents
that possess different mode of actions.
TGF-b singling antagonists in the late-stage (phase II/III)
clinical development for the treatment of fibrotic disorders
are protein-based molecules such as anti-TGF-b antibodies.
Initial efforts have been focused on the development of
antibody-based TGF-b antagonists because the primary
target for the TGF-b signaling pathway is a heterodimeric
TGF-b receptor kinase and it was thought that it would be
very difficult to develop a small molecule drug that very
specifically inhibits the TGF-b receptor kinase such as ALK5.
Many small molecule ALK5 inhibitors that are being
developed possess the ATP-competitive nature and the
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Figure 11 | Suppression of fibronectin expression in UUO control kidneys by IN-1130. (a) Representative Western blotting photograph
(upper panel) showing levels of fibronectin protein in kidneys of sham-operated rats, UUO control rats, and UUO rats once daily treated with
IN-1130 for 7 and 14 days. The same blot was stripped and reprobed with b-actin to confirm equal loading (lower panel). Numbers 1
and 2 indicate two individual animals from each group. (b) Quantitative analysis of the relative abundance of fibronectin protein after
normalization with b-actin. Values (fold induction relative to sham control) are s.e.m. of 7 (day 7) or 4 (day 14) animals per group. *Po0.05
versus sham control group. **Po0.01 versus sham control group. #Po0.05 versus UUO control group. ##Po0.01 versus UUO control group.
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unique mechanism of action. There are several advantages
inherent in these small molecule ALK5 inhibitors in terms
of the drug delivery efficiency. Orally bioavailable small
molecule ALK5 inhibitors may overcome the limit of tissue
penetration and delivery issues of anti-TGF-b antibody
therapies.
In conclusion, we demonstrate for the first time that
IN-1130 possesses evident protective effects on renal
interstitial fibrosis in UUO rats. Our study provides an
encouraging example of the therapeutic potential of modu-
lating TGF-b signaling in progressive renal fibrosis and is
indicative of the potential success of IN-1130 in the treatment
of renal fibrosis.
MATERIALS AND METHODS
DNA expression constructs and in vitro ALK5 inhibition assay
Wild-type full-length ALK5 and Smad3 complementary DNAs
were cloned by a polymerase chain reaction (PCR), as described
previously.38 The cytoplasmic region (amino acids 154–498) of
ALK5 was then amplified. Constitutively active ALK5 (T204D) was
made by mutating threonine (T) at position 204 in wild-type ALK5
to aspartic acid (D) using a PCR with Pfu polymerase (Stratagene,
La Jolla, CA, USA) with primers containing the designed mutations,
as described previously.39
N-terminal His-tagged kinase domain of constitutively active
ALK5 (T204D) and N-terminal His-tagged full-length Smad3
proteins were expressed in Sf9 insect cells using the BacNBlue
baculovirus expression system (Invitrogen, Carlsbad, CA, USA).
Proteins were purified with a Ni-NTA resin column (Qiagen,
Valencia, CA, USA). Purified Smad3 protein (200 ng) was mixed
with 100 ml of 0.1 M sodium bicarbonate coating buffer and plated
onto Flash-Plates (Perkin Elmer, Wellesley, MA, USA). Plates were
covered and incubated at 41C for 16 h. Plates were allowed to block
in 1% bovine serum albumin in phosphate-buffered saline at room
temperature for 1 h. Purified ALK5 protein (200 ng) in 200 ml of
reaction buffer (20 mM Tris-HCl, pH 7.4, 5 mM MgCl2, 1 mM CaCl2,
1 mM dithiothreitol, 1 mM ATP and 2 mCi g-32P-ATP) was mixed with
different concentrations of IN-1130. ALK5 reaction mixture was
added onto Smad3-coated plates and incubated at 301C for 3 h.
After incubation, the plates were washed three times with 200ml of
10 mM sodium pyrophosphate solution. After air drying, the
radioactivity was counted using Packard TopCount (Packard
instrument company, Meriden, CT, USA). The assays were run in
duplicate and repeated twice. IC50 value was calculated with
SigmaPlot software using a sigmoidal dose–response curve (n¼ 4).
Animal and experimental design
Six-week-old male Sprague–Dawley rats were purchased from Orient
Bio Inc. (Seoul, Republic of Korea). Rats weighing 180–200 g were
prepared. After a mid-abdominal incision under anesthesia using an
intraperitoneal injection of ketamine (35 mg/kg) and xylazine (9 mg/
kg), UUO was achieved by ligating the left ureter with 4-0 silk at two
points and cutting between ligatures. The animals that underwent
surgery were randomly divided into three groups: UUO plus vehicle
(n¼ 11), UUO plus low dose IN-1130 (10 mg/kg, n¼ 11), and UUO
plus high dose IN-1130 (20 mg/kg, n¼ 11). Sham-operated animals
(n¼ 11) were used as a control. Treatment started within 1 h after
surgical procedure. IN-1130 was prepared as described previously.26
Animals were intraperitoneally treated once daily with either vehicle
(saline) or IN-1130 for 7 (for each group, n¼ 7) or 14 (for each
group, n¼ 4) days. Animals were maintained in a temperature-
controlled room (at 241C) and supplied with autoclaved food and
water ad libitum. At 7 and 14 days post-surgery, animals were killed,
and the left kidneys were removed. The kidneys were sagittally sliced
into several parts, snap frozen in liquid nitrogen and kept at 801C.
A part of kidneys was immersed into 10% neutral-buffered formalin
for histopathological and immunohistochemical examinations. All
experimental procedures were conducted in accordance with our
institutional guidelines.
Quantitative real-time PCR analyses
Total RNA was isolated using Trizol reagent (Invitrogen) according
to the manufacturer’s instruction. Reverse transcription was
performed using the ultra high-frequency reverse transcriptase-
PCR system kit (Strategene). Synthesized complementary DNA was
amplified by a standard PCR protocol using iQTM SYBRs Green
supermix (Bio-Rad, Hercules, CA, USA) and rat-specific primers for
type 1 collagen (forward: 50-GGGACTTACCTCACTGCTTTTC-30;
reverse: 50-AATCACGACGCTGGGACTG-30) and for TGF-b1 (for-
ward: 50-CGGACTACTACGCCACCGCCGT-30; reverse: 50-TGGTTT
TGTCATAGATTGCGTT-30). Parallel amplifications with primers
for hypoxanthine phosphoribosyltransferase (HPRT) (forward:
50-GGGACTTACCTCACTGCTTTTC-30; reverse: 50-AATCACGACG
CTGGGACTG-30) were performed. Cycling conditions were: 3 min
preincubation at 951C, 15 s denaturation at 951C, 30 s annealing at
581C for 40 cycles using iCycler (Bio-Rad). The fluorescent product
was detected at the end of each cycle. Product specificity was
confirmed by agarose gel electrophoresis and routinely by melting-
curve analysis. Real-time PCR data were analyzed by using iCycler
software (Bio-Rad). The ratios of type 1 collagen and TGF-b1 to
HPRT mRNAs were calculated in each sample.
Additionally, synthesized complementary DNA as described
above was amplified by a standard PCR protocol using Taq poly-
merase and rat-specific primers for TGF-b1 and for type I collagen.
Parallel amplifications with primers for HPRT were performed.
The numbers of cycles (between 21 and 24) giving the linear range
and annealing temperatures (between 58 and 601C) were adjusted
depending on the genes amplified. Reaction products were electro-
phoresed on 2.0% agarose gels.
Western blotting analyses
Kidney tissue lysates were prepared by homogenization of frozen
tissues in radioimmunoprecipitation assay buffer containing, 0.5%
sodium deoxycholate, 100 mg/ml phenylmethanesulfonyl fluoride,
1% protease inhibitor cocktail, and 1% phosphatase inhibitor
cocktail (Sigma, St Louis, MO, USA). The lysates were cleared by
centrifugation at 13 000 g at 41C for 20 min. The protein content
of the lysates was determined using the bicinchoninic acid protein
assay kit (Pierce, Rockford, IL, USA).
Proteins (20–50 mg) were separated by 6–10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, and then transferred to
nitrocellulose membranes (Amersham Biosciences, Piscataway, NJ,
USA). The membranes were probed with appropriate antibodies in
blocking buffer including 5% bovine serum albumin or 5% nonfat
milk overnight at 41C. The primary antibodies were rabbit anti-
phospho-Smad2 (Cell Signaling Technology, Beverly, MA, USA),
mouse anti-a-SMA (Sigma), mouse anti-fibronectin (BD Bio-
sciences, San Jose, CA, USA), and mouse anti-b-actin (Sigma).
The blots were incubated with appropriate secondary immuno-
globulin G-peroxidase conjugates (1:10,000 dilution; Kirkegaard
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Perry Laboratories, Gaithersburg, MD, USA), and developed using
the enhanced chemiluminescence method. Band intensities were
analyzed using a densitometer (Model GS-690; Bio-Rad) equipped
with the Multi-Analyst software program (Version 1.01; Bio-Rad).
For quantification, the densities of the signals were normalized to
that for b-actin.
Determination of kidney hydroxyproline content
Kidneys were completely hydrolyzed in 6 M HCl at 1101C for 20 h.
The obtained dried pellets were reconstituted with citrate-acetate
buffer (pH 6.0) containing 0.2 M citric acid, 0.2 M glacial acetic acid,
0.4 M sodium acetate, and 0.85 M sodium hydroxide. Samples were
oxidized by 100 ml of chloramines-T solution (0.282 g chloramines-T
added to 16 ml citrate-acetate buffer, 2.0 ml of n-propanol, and
2.0 ml H2O). After incubating the mixture for 20 min at room
temperature, 100ml of Ehrlich’s solution (2.5 g of p-dimethylamino-
benzaldehyde added to 9.3 ml of n-propanol and 3.9 ml of 70%
perchloric acid) was added, and the samples were incubated for
30 min at 651C. The absorbance of each sample was measured at
570 nm using a spectrophotometer. Hydroxyproline content was
calculated from the standard curve constructed with hydroxy-L-
proline (Sigma). The results were expressed as hydroxyproline per
mg protein. Protein was determined using the bicinchoninic acid
protein assay kit (Pierce).
Histopathological examination
Fixed tissues in 10% neutral-buffered formalin were dehydrated in
graded alcohol and embedded in paraffin. Paraffin sections (5mm
thick) were stained with hematoxylin–eosin or with Masson’s-
modified trichrome.
Immunohistochemical examination
For immunohistochemical analysis, paraffin-embedded sections
(5mm) were deparaffinized, washed with phosphate-buffered saline
and treated with 3% H2O2 for 5 min. An antigen retrieval protocol
in which sections were heated in 10 mM citrate buffer (pH 6.0) for
10 min was used for pSmad2 immunohistochemistry. Sections were
blocked with 10% normal goat serum in Tris-HCl-buffered saline or
horse serum in phosphate-buffered saline for 1 h and then incubated
with either anti-pSmad2 (1:2000) antibody at 41C overnight or with
a-SMA (1:200) antibody diluted in blocking solution for 1 h at room
temperature. After washing, sections were incubated with appro-
priate biotin-conjugated secondary immunoglobulin G, and then
treated with reagents from a Vecta-Elite streptavidin-peroxidase kit
(Vector Laboratories, Burlingame, CA, USA) with a benzidine
substrate for color development. Sections were counterstained with
diluted hematoxylin.
Statistical analyses
Quantitation of Western blotting data was performed by measuring
the intensity of the signals using Quantity One Image analysis
software (Bio-Rad). Data are expressed as s.e.m. Differences between
groups were examined for statistical significance by using analysis of
variance. Statistical analysis of the data was performed further by
using least significant difference test between the two groups.
Po0.05 were considered to be significant.
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